Optimer granted Astellas exclusive rights to develop and commercialize fidaxomicin in Europe and countries in the Middle East, Africa and the Commonwealth of Independent States (CIS)

Optimer Pharmaceuticals Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$514.0m on 02/11/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Astellas Pharma Inc.

Japan / Mid-Cap Biopharma ($1-$50 billion)

$18,580.0m on 02/11/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced